Moderna mFlusiva Wins Unanimous VRBPAC Vote; NovoCure TRIDENT Fails in GBM

The US just opened a formal trade probe into Germany's drug pricing overhaul — and if you have European revenue exposure, this is your problem starting today.

That plus Treasury eyeing investment screens on Chinese biotech, a four-hundred-million-dollar IPO that popped thirty-one percent, and a unanimous FDA panel endorsement for Moderna's flu shot. Packed Friday — let's go.

Welcome to The Pharma Closeout for Friday, June nineteenth, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Let's close out the week.

Top story is trade policy colliding with pharma economics on two fronts simultaneously. The US government has launched a formal probe into Germany's plan to cut drug prices. Germany is the largest pharma market in Europe, and its pricing reforms have historically set the benchmark for the continent. When Germany moves, France, Italy, and Spain recalibrate within a year or two. The probe is not really about Berlin — it is about preventing a continental repricing wave that would compress net revenue forecasts for every major company doing health technology assessment submissions in Europe.

Forget the irony of an administration pushing domestic price negotiations while blocking them overseas. The functional issue is cascade risk. Germany's reference pricing decisions have consistently triggered downstream revisions across European HTA bodies. The probe tells you the administration has mapped the same domino sequence — and decided trade tools are the intervention point. For companies modeling European revenue growth, this is a variable that was not in the base case a week ago.

The second front landed yesterday. Endpoints broke an exclusive that Treasury is evaluating screening mechanisms for American investments flowing into Chinese biotech. This goes well beyond BIOSECURE Act territory. Investment screening would reach into venture capital flows, licensing partnerships, and CRO contracts. The scope is broader and the mechanism is more aggressive.

It immediately reprices optionality on every existing Chinese partnership. Companies maintaining active licensing agreements out of China now face a higher cost of that option — not because screening is certain, but because the political trajectory has made the tail risk materially heavier. And anyone running clinical programs through Chinese CROs has a new planning variable that did not exist ten days ago.

We said in April that the trade front was the one to watch and the question was which countries come next. Germany and China surfacing in the same week gives you a definitive answer.

The shift is in tool selection. Tariffs hit the price of finished goods. Investment screening and trade probes hit the infrastructure of how pharma operates globally — how deals get structured, where trials get run, how partnerships get maintained. If you run business development with meaningful European or Chinese exposure, this week compressed your planning timeline.

Shifting to the deal side — that geopolitical backdrop actually makes the domestic capital markets story more striking. Kardigan, the heart drug developer, raised four hundred million dollars in an upsized IPO Thursday, with shares surging thirty-one percent above the offering price. This year's IPO class has now produced five of the six largest new biotech stock offerings since the start of twenty twenty-two.

Cardiovascular names are pulling outsized investor appetite right now. But the test for this IPO class arrives in six to twelve months, when newly public programs start reporting pivotal data against public market expectations. The longer this streak runs without a high-profile post-IPO miss, the more crowded the exit gets when one finally lands.

Let's bring in Marcus Webb on one of the week's bigger deals. Jazz Pharmaceuticals partnered with AbCellera on T cell engagers targeting GI cancers, in a collaboration valued at up to four point one billion dollars.

The biology is the constraint. T cell engagers in solid tumors face a tumor microenvironment problem that has humbled multiple programs ahead of this one. Jazz is paying for AbCellera's antibody engineering platform to solve what is fundamentally a biophysics challenge — and that carries a meaningfully different risk profile than licensing a clinical-stage molecule with existing human data.

On the bolt-on front — Lilly acquired 4E Therapeutics, a non-opioid pain biotech. No deal value disclosed, but per BioPharma Dive, Lilly has now put more than eighteen billion into acquisitions over the past few years. Non-opioid pain is high unmet need with strong regulatory tailwinds. Biogen separately announced an up-to-one-billion-dollar buyout of secretive anti-inflammatory startup RayThera for immunology. And Pfizer CFO Dave Denton is stepping down August fifteenth to return to consumer goods, with Cecile taking over as interim while the search runs. Shares slipped Thursday on the news.

The Pfizer departure adds leadership uncertainty at a moment when the portfolio transition demands financial discipline. Who they bring in — pharma insider versus cross-industry hire — tells you what restructuring story the board is writing next. And on pipeline data, Edgewise Biosciences reported positive topline results in hypertrophic cardiomyopathy, but the differentiation question from mavacamten and aficamten is still unresolved. Positive topline in HCM clears a low bar — formulary positioning in this class depends on the cardiac tolerability signal at sustained therapeutic exposure, and that data has not arrived.

On the regulatory front, the headline belongs to Moderna. The FDA's vaccine advisory committee voted unanimously to back Moderna's flu vaccine, mFlusiva. This is the same shot the agency controversially refused to even file for review earlier this year under former Commissioner Makary. A unanimous panel endorsement is as close to an institutional course correction as you will see from FDA.

If approved at the August fifth PDUFA, mFlusiva becomes Moderna's first commercial product outside of COVID vaccines. Unanimous advisory committee votes historically translate to approvals — the real variable now is label scope.

And that is where the commercial trajectory gets shaped. The label question that matters is how the FDA characterizes immunogenicity — specifically whether the framing supports a non-inferiority position or opens the door to a superiority argument against established flu franchises from Sanofi and CSL Seqirus. That single regulatory paragraph shapes Moderna's payer negotiation leverage for years.

Two more items. The FDA approved a label expansion for Merck's pneumococcal vaccine Capvaxive — details on the new indication are still emerging, but any broadening of the adult pneumococcal recommendation feeds directly into the competitive dynamic with Pfizer's Prevnar franchise. And the FTC is requiring Aurobindo Pharma to divest four drug products as a condition of completing its Lannett acquisition — standard antitrust remedy, but it sets the divestiture template for generic consolidation deals going forward.

One setback to flag. Traws Pharma dropped eighteen point two percent to a dollar five in pre-market after deferring its Phase 2a influenza study of tivoxavir marboxil following a negative UK MHRA review. At that share price, regulatory friction from a non-US agency is near-existential. Separately, Sanofi halted an immune drug trial this week — limited details available, but another data point in a choppy stretch for their mid-stage pipeline.

The Traws story reinforces the geopolitical thread from our top story — non-US regulatory signals are increasingly driving US equity moves. And one broader policy signal worth flagging — there are indications the FDA is offering CRL recipients a fresh path to re-engage on previously rejected applications. If that shift solidifies, it changes the calculus for programs that were functionally written off.

Looking ahead — Moderna's August fifth PDUFA is the marquee regulatory date on the calendar. The Pfizer CFO search will signal financial strategy direction. And any concrete rulemaking on Treasury's China investment screening would immediately reprice risk across the sector.

On the venture side, keep your radar on this week's launches. cAMPfield debuted with a hundred and eighty million for gut disease. Vedana emerged with forty-six million for anti-PACAP migraine therapies — that is a receptor target gaining real traction as a differentiated approach to prevention. Spot Bio launched with forty million for non-viral gene therapy in muscular dystrophy. And Innoviva revived Lyndra's long-acting oral drug platform this week with Bob Langer and Janet Woodcock as advisors — that combination of formulation science and regulatory credibility is worth watching. Venture deployment at this pace signals where the acquisition targets surface eighteen to twenty-four months out.

Those venture bets are worth tracking alongside the geopolitical story — because in a world where Chinese partnerships get more complex and European pricing gets squeezed, domestically focused platform companies with differentiated biology become significantly more attractive acquisition targets.

That is your Pharma Closeout for Friday, June nineteenth. From the Germany pricing probe and Treasury's China screening moves, to Kardigan's four-hundred-million-dollar IPO, Jazz's four-billion-dollar T cell engager bet with AbCellera, Moderna's unanimous panel win, and Pfizer's CFO exit — a week that started on deals and ended on geopolitics. If this briefing keeps you sharp, follow us on Spotify and drop a rating — it is the fastest way to help other pharma professionals find the show. We are back Sunday with the full week in review.

Have a great weekend. See you Sunday. ### Episode Metadata **Title:** US Probes Germany Drug Pricing; Moderna Flu Vaccine Wins Unanimous FDA Panel; Jazz-AbCellera $4.1B T Cell Engager Deal | Jun 19, 2026 **Description:** US government opens formal probe into Germany's drug pricing reforms, escalating transatlantic pharma trade tensions. Kardigan IPO raises $400M and pops 31%. Moderna flu vaccine gets unanimous FDA advisory panel support ahead of Aug 5 PDUFA. Jazz and AbCellera strike $4.1B T cell engager collaboration. **Tags:** Germany drug pricing, US trade probe, Moderna flu vaccine, mFlusiva, Kardigan IPO, Jazz Pharmaceuticals, AbCellera, T cell engagers, Pfizer CFO Dave Denton, Eli Lilly, 4E Therapeutics, Edgewise Biosciences, HCM, Biogen, RayThera, Traws Pharma, tivoxavir marboxil, Merck Capvaxive, Treasury China biotech, cAMPfield, Vedana Therapeutics, Spot Bio, Innoviva, Lyndra, Sanofi, Aurobindo, Lannett, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #